Middle East and Africa Menstrual Cramps Treatment Market – Industry Trends and Forecast to 2028

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Middle East and Africa Menstrual Cramps Treatment Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Publish Reports
  • Jan 2021
  • MEA
  • 350 Seiten
  • Anzahl der Tabellen: 231
  • Anzahl der Abbildungen: 43

Middle East and Africa Menstrual Cramps Treatment Market, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End User (Hospitals, Specialty Centers, Ambulatory Surgical Centers, Others), Distribution Channel (Pharmacies, Retail Sales, Direct Tender, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Middle East and Africa Menstrual Cramps Treatment Market

Market Analysis and Insights : Middle East and Africa Menstrual Cramps Treatment Market

The menstrual cramps treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2021 to 2028 and is expected to reach USD 201.01 million by 2028. Rising pharmaceutical industries interest for the manufacturing plant and rising prevalence of menstrual diseases in the region are the major drivers propelling the demand of the menstrual cramps treatment market in the forecast period.

Menstrual cramps are the cramping and throbbing pain in the lower abdomen of the body. Many women have menstrual cramps before and after the menstrual periods. For some women menstrual cramps are common while for other women menstrual cramps are annoying and quite severe which interfere in daily activities for few days of every month. Symptoms of menstrual cramps are pain that starts 1 to 3 days before the period, peaks 24 hours after the onset of the period and subsides in 2 to 3 days along with dullness, continuous ache, nausea, headache, dizziness, loose stools and others.

Menstrual cramps treatment comprises features such as increasing need for effective treatment for menstrual cramps will impact in launching of new product by the manufacturers into the market which enhances its demand as well as rising government & pharmaceutical industries initiatives leads to the menstrual cramps treatment market growth. The use of alternative therapies acts as a challenge for the growth of the menstrual cramps treatment market.

Currently, awareness programmes are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative technology. Moreover, these awareness programmes are also expected to provide various other opportunities in the menstrual cramps treatment market. However, presence of traditional therapies is expected to restraint the menstrual cramps treatment market growth in the forecast period.

The menstrual cramps treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the menstrual cramps treatment market scenario contact Data ridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Menstrual Cramps Treatment Market

Menstrual Cramps Treatment Market Scope and Market Size

The menstrual cramps treatment market is segmented on the basis of the type, treatment type, mode of prescription, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. In 2021, primary dysmenorrhea segment is dominating the menstrual cramps treatment market as women in the Middle East and Africa suffering from or faces menstrual cramps during their periods.
  • On the basis of treatment type, the menstrual cramps treatment market is segmented into medication, therapy, surgery and others. In 2021, medication segment is dominating the menstrual cramps treatment market since medication of nonsteroidal anti-inflammatory drugs and combined oral contraceptives represent first-line therapy for dysmenorrhea pain.
  • On the basis of mode of prescription, the menstrual cramps treatment market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating the menstrual cramps treatment market as most of the drugs are available in generic and supply of pharmaceutical products without any hindrance raises awareness among the masses by the virtues of advertising.
  • On the basis of route of administration, the menstrual cramps treatment market is segmented into oral, parenteral, implants and others. In 2021, oral segment is dominating the menstrual cramps treatment market as oral segment is considered to be the first line of treatment.
  • On the basis of end user, the menstrual cramps treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers and others. In 2021, hospitals segment is dominating the menstrual cramps treatment market because most of the patients are experiencing menopausal symptoms so they would be seen in the hospitals to get proper diagnosis and treatment.
  • On the basis of distribution channel, the menstrual cramps treatment market is segmented into direct tender, retail sales, pharmacies and others. In 2021, pharmacies segment is dominating the menstrual cramps treatment market as variety of medicines available in the pharmacies is according to the patient needs and demand.

Middle East and Africa Menstrual Cramps Treatment Market Country Level Analysis

Middle East and Africa menstrual cramps treatment market is analysed and market size information is provided by the country, type, treatment type, mode of prescription, route of administration, end user and distribution channel as referenced above.

The countries covered in the Middle East and Africa menstrual cramps treatment market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa.

Mode of prescription segment in Middle East and Africa menstrual cramps treatment market is expected to dominate due to the high adoption of OTC menstrual cramps treatment by the patients in the region. Saudi Arabia is dominating in the Middle East and Africa menstrual cramps treatment market and leading the growth due to rising presence of key market players in the region. South Africa holds the second highest market share because of rising healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic Initiatives by Manufacturers is creating new opportunities for Players in the Menstrual Cramps Treatment Market

Menstrual cramps treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with menstrual cramps treatment sales, impact of advancement in the menstrual cramps treatment and changes in regulatory scenarios with their support for the menstrual cramps treatment market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Menstrual Cramps Treatment Market Share Analysis

Menstrual cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to menstrual cramps treatment market.

The major companies which are dealing in the Middle East and Africa menstrual cramps treatment market report are Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Mylan N. V. (a part of Viatris Inc.), Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., LIVIA, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the menstrual cramps treatment market.

For instance,

  • In October 2020, Bayer AG launched its first Global Creative Council. The fundamental aim of this launch is raising the bar for the Consumer Health Industry. It is predicted that this launch has anticipated bolstering the company presence in healthcare market.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the menstrual cramps treatment market which also provides the benefit for organisation to improve their offering for menstrual cramps treatment.


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

4.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

6.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE

6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS

6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 GROWING PREVALENCE OF DYSMENORRHEA

9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS

9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES

9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE

9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS

9.2 RESTRAINTS

9.2.1 PRODUCT RECALLS

9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN

9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY

9.3 OPPORTUNITIES

9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 RISING DISPOSABLE INCOME

9.4 CHALLENGES

9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT

9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT

9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY DYSMENORRHEA

10.3 SECONDARY DYSMENORRHEA

11 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 FIRST LINE TREATMENT

11.2.1.1 Nonhormonal Therapy

11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs

11.2.1.1.1.1 Ibuprofen

11.2.1.1.1.2 Naproxen

11.2.1.1.1.3 Celecoxib

11.2.1.1.1.4 Mefenamic Acid

11.2.1.1.1.5 Meclofenamate

11.2.1.1.2 Acetaminophen

11.2.1.2 Hormonal Replacement Therapy y

11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)

11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol

11.2.1.2.1.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol

11.2.1.2.2.2 Others

11.2.1.2.3 Other

11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol

11.2.1.2.3.2 Etonogestrel Implant

11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System

11.2.1.2.3.4 Medroxyprogesterone Shot

11.2.1.3 Diuretic

11.2.1.3.1 Spironolactone

11.2.1.3.2 Ammonium Chloride

11.2.1.4 Antidepressants

11.2.2 SECOND LINE TREATMENT

11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy

11.2.2.2 Ammonium Chloride

11.3 THERAPY

11.3.1 HEAT THERAPY

11.3.1.1 Patch

11.3.1.2 Wrap

11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)

11.3.2 BEHAVIORAL COUNSELING

11.3.2.1 Desensitization-Based Procedures

11.3.2.2 Coping Strategies

11.3.2.3 Imagery

11.3.2.4 Hypnotherapy

11.3.2.5 Others

11.3.3 DIET AND VITAMINS

11.3.3.1 Vitamin E

11.3.3.2 Vitamin B

11.3.3.3 Vitamin D

11.3.3.4 Others

11.4 SURGERY

11.4.1 ENDOMETRIAL ABLATION

11.4.2 HYSTERECTOMY

11.5 OTHERS

12 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION

13 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLETS

13.2.2 PILLS

13.2.3 CAPSULE

13.2.4 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 IMPLANTS

13.5 OTHERS

14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CENTERS

14.4 AMBULATORY SURGICAL CENTERS

14.5 OTHERS

15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 PHARMACIES

15.2.1 HOSPITAL

15.2.2 RETAIL

15.3 DIRECT TENDER

15.4 RETAIL SALES

15.5 OTHERS

16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

16.1 MIDDLE EAST & AFRICA

16.1.1 SAUDI ARABIA

16.1.2 SOUTH AFRICA

16.1.3 UAE

16.1.4 ISRAEL

16.1.5 KUWAIT

16.1.6 EGYPT

16.1.7 REST OF MIDDLE EAST & AFRICA

17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GLAXOSMITHKLINE PLC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANLYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 ABBVIE INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MYLAN N. V. (A PART OF VIATRIS INC.).

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ALVOGEN

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BAYER AG

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 BEURER GMBH

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOELECTRONICS CORPORATION

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 COLOR SEVEN CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 CUMBERLAND PHARMACEUTICALS INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 LIVIA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MYOVANT SCIENCES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NOBELPHARMA CO., LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 OBSEVA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 PFIZER INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 PMS4PMS, LLC

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 SANOFI

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Tabellenverzeichnis

LIST OF TABLES

TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS

TABLE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 8 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 52 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 53 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 78 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 79 SAUDI ARABIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 SAUDI ARABIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 SAUDI ARABIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 101 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 103 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 104 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 105 SOUTH AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 106 SOUTH AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 107 SOUTH AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 108 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 109 SOUTH AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 110 SOUTH AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 111 SOUTH AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 112 SOUTH AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 113 SOUTH AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 114 SOUTH AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 115 SOUTH AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 116 SOUTH AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 117 SOUTH AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 118 SOUTH AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 119 SOUTH AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 120 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 121 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 SOUTH AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 SOUTH AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 SOUTH AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 129 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 130 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 131 UAE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 132 UAE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 133 UAE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 134 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 135 UAE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 136 UAE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 137 UAE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 138 UAE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 139 UAE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 140 UAE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 141 UAE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 142 UAE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 143 UAE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 144 UAE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 145 UAE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 146 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 147 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 UAE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 149 UAE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 151 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 152 UAE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 155 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 156 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 157 ISRAEL MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 158 ISRAEL FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 159 ISRAEL NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 160 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 161 ISRAEL HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 162 ISRAEL COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 163 ISRAEL EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 164 ISRAEL OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 165 ISRAEL DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 166 ISRAEL SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 167 ISRAEL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 168 ISRAEL HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 169 ISRAEL BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 170 ISRAEL DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 171 ISRAEL SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 172 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 173 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 174 ISRAEL ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 175 ISRAEL PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 176 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 ISRAEL PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 179 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 181 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 182 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 183 KUWAIT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 184 KUWAIT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 185 KUWAIT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 186 KUWAIT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 187 KUWAIT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 188 KUWAIT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 189 KUWAIT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 190 KUWAIT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 191 KUWAIT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 192 KUWAIT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 193 KUWAIT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 194 KUWAIT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 195 KUWAIT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 196 KUWAIT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 197 KUWAIT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 198 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 199 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 KUWAIT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 KUWAIT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 203 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 204 KUWAIT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 205 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 206 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 207 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 208 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 209 EGYPT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 210 EGYPT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 211 EGYPT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 212 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 213 EGYPT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 216 EGYPT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 217 EGYPT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 218 EGYPT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 219 EGYPT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 220 EGYPT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 221 EGYPT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 222 EGYPT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 223 EGYPT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 224 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 225 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 226 EGYPT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 227 EGYPT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 229 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 230 EGYPT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 REST OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

 

Abbildungsverzeichnis

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028

FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

FIGURE 14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020

FIGURE 15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020

FIGURE 19 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)

FIGURE 21 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020

FIGURE 23 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 29 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020

FIGURE 31 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 39 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 40 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)

FIGURE 43 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Middle East and Africa Menstrual Cramps Treatment Market size will be worth USD 201.01 million by 2028.
The Middle East and Africa Menstrual Cramps Treatment Market growth rate will be 6.2% by 2028.
The Rising pharmaceutical industries interest for the manufacturing plant and rising prevalence of menstrual diseases in the region are the growth drivers of the Middle East and Africa Menstrual Cramps Treatment Market.
The type, treatment type, mode of prescription, route of administration, end user and distribution channel are the factors on which the Middle East and Africa Menstrual Cramps Treatment Market research is based.
The major companies in the Middle East and Africa Menstrual Cramps Treatment Market are Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Mylan N. V. (a part of Viatris Inc.), Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., LIVIA, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd.